SEARCH

SEARCH BY CITATION

References

  • Ali N. J. and Levine M. S. (2006) Changes in expression of N-methyl-D-aspartate receptor subunits occur early in the R6/2 moue model of Huntington disease. Dev. Neurosci. 28, 230238.
  • Anderson W. W. and Collingridge G. L. (2001) The LTP Program: a data acquisition program for on-line analysis of long-term potentiation and other synaptic events. J. Neurosci. Methods 15, 7183.
  • Bemelmans A. P., Horellou P., Pradier L., Brunet I., Colin P. and Mallet J. (1999) Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer. Hum. Gene Ther. 10, 29872997.
  • Caldeira M. V., Melo C. V., Pereira D. B., Carvalho R. F., Carvalho A. L. and Duarte C. B. (2007) BDNF regulates the expression and traffic of NMDA receptors in cultured hippocampal neurons. Mol. Cell. Neurosci. 35, 208219.
  • Cattaneo E. and Conti L. (1998) Generation and characterization of embryonic striatal conditionally immortalized ST14A cells. J. Neurosci. Res. 53, 223234.
  • Cattaneo E., Zuccato C. and Tartari M. (2005) Normal huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 6, 919930.
  • Cepeda C., Colwell C. S., Itri J. N., Gruen E. and Levine M. S. (1998) Dopaminergic modulation of early signs of excitotoxicity in visualized rat neostriatal neurons. Eur. J. Neurosci. 10, 34913497.
  • Cepeda C., Ariano M. A., Calvert C. R., Flores-Hernández J., Chandler S. H., Leavitt B. R., Hayden M. R. and Levine M. S. (2001) NMDA receptor function in mouse models of Huntington disease. J. Neurosci. Res. 66, 525539.
  • Cha J. H., Frey A. S., Alsdorf S. A., Kerner J. A., Kosinski C. M., Mangiarini L., Penney J. B., Jr, Davies S. W., Bates G. P. and Young A. B. (1999) Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 354, 981989.
  • Crozier R. A., Bi C., Han Y. R. and Plummer M. R. (2008) BDNF modulation of NMDA receptors is activity dependent. J. Neurophysiol. 100, 32643274.
  • Cull-Candy S., Brickley S. and Farrant M. (2001) NMDA receptor subunits: diversity, development and disease. Curr. Opin. Neurobiol. 11, 327335.
  • Dingledine R., Borges K., Bowie D. and Traynelis S. F. (1999) The glutamate receptor ion channels. Pharmacol. Rev. 51, 761.
  • Diógenes M. J., Fernandes C. C., Sebastião A. M. and Ribeiro J. A. (2004) Activation of adenosine A2A receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in hippocampal slices. J. Neurosci. 24, 29052913.
  • Diógenes M. J., Assaife-Lopes N., Pinto-Duarte A., Ribeiro J. A. and Sebastião A. M. (2007) Influence of age on BDNF modulation of hippocampal synaptic transmission: interplay with adenosine A2A receptors. Hippocampus 17, 577585.
  • Domenici M. R., Scattoni M. L., Martire A., Lastoria G., Potenza R. L., Borioni A., Venerosi A., Calamandrei G. and Popoli P. (2007) Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice. Neurobiol. Dis. 28, 197205.
  • Ehrlich M. E., Conti L., Toselli M. et al. (2001) ST14A cells have properties of a medium-size spiny neuron. Exp. Neurol. 167, 215226.
  • Ferrante A., Martire A., Armida M., Chiodi V., Pézzola A., Potenza R. L., Domenici M. R. and Popoli P. (2010) Influence of CGS 21680, a selective adenosine A2A receptor agonist, on NMDA receptor function and expression in the brain of Huntington's disease mice. Brain Res. 1323, 184191.
  • Gauthier L. R., Charrin B. C., Borrell-Pages M. et al. (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118, 127138.
  • Gavalda N., Perez-Navarro E., Gratacos E., Comella J. X. and Alberch J. (2004) Differential involvement of phosphatidylinositol 3-kinase and p42/p44 mitogen activated protein kinase pathways in brain-derived neurotrophic factor induced trophic effects on cultured striatal neurons. Mol. Cell. Neurosci. 25, 460468.
  • Glass M., Dragunow M. and Faull R. L. (2000) The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97, 505519.
  • Gomes J. R., Costa J. T., Melo C. V. et al. (2012) Excitotoxicity downregulates TrkB.FL signaling and upregulates the neuroprotective truncated TrkB receptors in cultured hippocampal and striatal neurons. J. Neurosci. 32, 46104622.
  • Heng M. Y., Detloff P. J., Wang P. L., Tsien J. Z. and Albin R. L. (2009) In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J. Neurosci. 29, 32003205.
  • Ji Y., Lu Y., Yang F., Shen W., Tang T. T., Feng L., Duan S. and Lu B. (2010) Acute and gradual increases in BDNF concentration elicit distinct signaling and functions in neurons. Nat. Neurosci. 13, 302309.
  • Knüsel B. and Hefti F. (1992) K-252 compounds: modulators of neurotrophin signal transduction. J. Neurochem.. 59, 19871996.
  • Lee F. S. and Chao M. V. (2001) Activation of trk neurotrophin receptors in the absence of neurotrophins. Proc. Natl Acad. Sci. USA 98, 35553560.
  • Levine M. S., Klapstein G. J., Koppel A. et al. (1999) Enhanced sensitivity to N-methyl-D aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res. 58, 515532.
  • Liu Y., Wong T. P., Aarts M. et al. (2007) NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J. Neurosci. 27, 28462857.
  • Mangiarini L., Sathasivam K., Seller M. et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493506.
  • Martire A., Calamandrei G., Felici F., Scattoni M. L., Lastoria G., Domenici M. R., Tebano M. T. and Popoli P. (2007) Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice. Neurosci. Lett. 417, 7883.
  • Martire A., Ferrante A., Potenza R. L., Armida M., Ferretti R., Pézzola A., Domenici M. R. and Popoli P. (2010) Remodeling of striatal NMDA receptors by chronic A2A receptor blockade in Huntington's disease mice. Neurobiol. Dis. 37, 99105.
  • Minghetti L., Greco A., Potenza R. L., Pezzola A., Blum D., Bantubungi K. and Popoli P. (2007) Effects of the adenosine A2A receptor antagonist SCH58621 on cyclooxygenase-2 expression, glial activation and BDNF availability in a rat model of striatal neurodegeneration. J. Neuropathol. Exp. Neurol. 66, 363371.
  • Pattwell S. S., Bath K. G., Perez-Castro R., Lee F. S., Chao M. V. and Ninan I. (2012) The BDNF Val66Met polymorphism impairs synaptic transmission and plasticity in the infralimbic medial prefrontal cortex. J. Neurosci. 32, 24102421.
  • Potenza R. L., Tebano M. T., Martire A., Domenici M. R., Pepponi R., Armida M., Pèzzola A., Minghetti L. and Popoli P. (2007) Adenosine A2A receptors modulate BDNF both in normal conditions and in experimental models of Huntington's disease. Purinergic Signal. 3, 333338.
  • Pousinha P. A., Diógenes M. J., Ribeiro J. A. and Sebastião A. M. (2006) Triggering of BDNF facilitatory action on neuromuscular transmission by adenosine A2A receptors. Neurosci. Lett. 404, 143147.
  • Reddy P. H., Charles V., Williams M., Miller G., Whetsell W. O., Jr and Tagle D. A. (1999) Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 354, 10351045.
  • Tapley P., Lamballe F. and Barbacid M. (1992) K252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors. Oncogene 7, 371381.
  • Tarditi A., Camurri A., Varani K., Borea P. A., Woodman B., Bates G., Cattaneo E. and Abbracchio M. P. (2006) Early and transient alteration of adenosine A(2A) receptor signaling in a mouse model of Huntington disease. Neurobiol. Dis. 23, 4453.
  • Tebano M. T., Martire A., Potenza R. L., Grò C., Pepponi R., Armida M., Domenici M. R., Schwarzschild M. A., Chen J. F. and Popoli P. (2008) Adenosine A2A receptors are required for normal BDNF levels and BDNF-induced potentiation of synaptic transmission in the mouse hippocampus. J. Neurochem. 104, 279286.
  • Tebano M. T., Martire A., Chiodi V., Pepponi R., Ferrante A., Domenici M. R., Frank C., Chen J. F., Ledent C. and Popoli P. (2009) Adenosine A2A receptors enable the synaptic effects of cannabinoid CB1 receptors in the rodent striatum. J. Neurochem. 110, 19211930.
  • The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971983.
  • del Toro D., Canals J. M., Gines S., Kojima M., Egea G. and Alberch J. (2006) Mutant huntingtin impairs the post-Golgi trafficking of brain-derived neurotrophic factor but not its Val66Met polymorphism. J. Neurosci. 26, 1274812757.
  • Torres-Peraza J. F., Giralt A., García-Martínez J. M., Pedrosa E., Canals J. M. and Alberch J. (2008) Disruption of striatal glutamatergic transmission induced by mutant huntingtin involves remodeling of both postsynaptic density and NMDA receptor signaling. Neurobiol. Dis. 29, 409421.
  • Traficante A., Riozzi B., Cannella M., Rampello L., Squitieri F. and Battaglia G. (2007) Reduced activity of cortico-striatal fibres in the R6/2 mouse model of Huntington's disease. NeuroReport. 18, 19972000.
  • Varani K., Rigamonti D., Sipione S., Camurri A., Borea P. A., Cattabeni F., Abbracchio M. P. and Cattaneo E. (2001) Aberrant amplification of A2A receptor signaling in striatal cells expressing mutant Huntingtin. FASEB J. 15, 12451247.
  • Varani K., Abbrachio M. P., Cannella M., Cislaghi G., Giallonardo P., Mariotti C., Cattabriga E., Borea P. A., Squitieri F. and Cattaneo E. (2003) Aberrant A2A receptor function in peripheral blood cells in Huntington's disease. FASEB J. 17, 21482150.
  • Vonsattel J. P. and DiFiglia M. (1998) Huntington disease. J. Neuropathol. Exp. Neurol. 57, 369384.
  • Vonsattel J. P., Myers R. H., Stevens T. J., Ferrante R. J., Bird E. D. and Richardson E. P., Jr (1985) Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44, 559577.
  • Zeron M. M., Hansson O., Chen N., Wellington C. L., Leavitt B. R., Brundin P., Hayden M. R. and Raymond L. A. (2002) Increased sensitivity to N-methyl-D-aspartate receptor mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33, 849860.
  • Zuccato C. and Cattaneo E. (2007) Role of brain-derived neurotrophic factor in Huntington's disease. Prog. Neurobiol. 81, 294330.
  • Zuccato C., Ciammola A., Rigamonti D. et al. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293, 493498.